Kazmira Therapeutics and CareValidate Launch Prescription CBD Telehealth

Kazmira Therapeutics announced on October 14, 2026, a partnership with CareValidate, a digital health infrastructure platform that powers telehealth brands, provider networks, prescription routing and pharmacy fulfillment, to deliver prescription, THC-free cannabidiol through a structured telemedicine pathway. According to the companies’ announcement, the product, called Prescription Cannabis Therapy, consists of non-intoxicating, THC-free CBD formulations compounded by a licensed 503A pharmacy against a prescription written by a licensed clinician.

Through the partnership, patients evaluated by independent licensed clinicians on CareValidate-powered telehealth programs can, when clinically appropriate, receive a prescription for compounded CBD formulated under license from Kazmira and made exclusively with Kazmira’s pharmaceutical-grade active ingredient. Prescriptions are routed through the CareValidate platform to Kazmira Pharmacy and other approved pharmacies, compounded to the patient’s prescribed dose, and shipped directly to the patient.

The announcement states that this access to prescription, THC-free CBD is immediately available in all 50 states. Kazmira Pharmacy’s website states that the pharmacy is licensed as a 503A compounding pharmacy in Colorado and currently prepares and dispenses compounded medications only for patients located in Colorado, with additional dispensing jurisdictions to be added as licensure is obtained. CareValidate’s program page states that Kazmira Pharmacy and its licensed partner hold the state licenses and fill every order, with eligibility confirmed by shipping state at intake.

December 2026 Federal Hemp Deadline

The companies set the partnership against a federal enforcement deadline for hemp-derived products. The announcement states that Congress has closed the hemp loophole that allowed intoxicating, hemp-derived products onto the over-the-counter market, with federal enforcement beginning in December 2026, after which, the companies state, the majority of retail CBD products sold today will fall outside the legal definition of hemp. CareValidate’s program page states that on December 11, 2026, a new federal rule caps hemp products at 0.4 mg of total THC per container and cites an industry estimate that roughly 95 percent of hemp-derived cannabinoid products sold today fall outside the new definition. The page states the prescription pathway is regulated under pharmacy law rather than the hemp definition, so neither the November 12 nor the December 11 deadline touches it. Kazmira states its pharmaceutical-grade, THC-free formulations and prescription-only model position the company and its partners as compliant operators past that deadline.

The companies also cite published research on dosing and labeling to support the prescription model. The announcement states that 54 percent of active CBD users take less than 50 mg per day, while clinical research shows efficacy requires a dose of 200 to 400 mg, and links to a study in the Journal of Cannabis Research as well as to a separate paper it describes as suggesting positive signals for CBD use in pets for several conditions. CareValidate’s page states that a typical retail CBD serving holds 5 to 20 mg, that most positive clinical trials used more than 300 mg a day, citing Chesney et al. (2020), and that about 7 in 10 CBD products sold online are mislabeled, citing Bonn-Miller et al. in the Journal of the American Medical Association (2017).

Storefront Partner Program

Kazmira and CareValidate are also inviting hemp and cannabinoid businesses facing the November deadline to apply to become Storefront Partners, a program the announcement frames as protecting businesses at risk of losing payment processing and advertising accounts while giving their customers access to CBD through a branded, regulated telehealth storefront. On CareValidate’s page, the program runs in four steps: the brand introduces the program through its existing storefront and customer list, with marketing assets supplied by Kazmira; a licensed clinician reviews the patient’s intake and medications, asynchronously or by a live visit where state rules require one, and decides whether prescription cannabidiol is appropriate; a LegitScript Certified pharmacy compounds the prescribed dose with Kazmira’s THC-free cannabidiol and ships it under the brand; and care continues with pharmacist check-ins, monthly refills and dose adjustments when appropriate. The page states marketing assets are pre-approved by Kazmira and that Kazmira fills prescriptions without marketing to the storefront’s patients.

Kazmira describes itself as the first vertically integrated cannabinoid company in the United States, combining pharmaceutical-grade cannabidiol API manufacturing, the Kazmira Pharmacy compounding operation and the Cope Now telehealth platform. Headquartered in Watkins, Colorado, the company also operates 1Cannabis, an education platform for prescription cannabinoid pharmacology aimed at clinicians and patients. Kazmira’s website states that it operates a pharmaceutical manufacturing facility in Colorado under cGMP and ICH Q7 standards, with ISO, cGMP and EPA compliance, and describes a three-entity ecosystem in which Kazmira Therapeutics handles API development, GMP production, research and governance. CareValidate’s page states that Kazmira was founded in 2016, launched the nation’s first 503A compounding pharmacy dedicated to prescription-only, THC-free CBD in January 2026, and launched its clinician education platform in April 2026. The prescription CBD is offered in three strengths, 6,000, 9,000 and 12,000 mg bottles, one for each prescribed daily dose, and the page attributes the formulation to a 29-step proprietary purification process; independent testing of a referenced batch found less than 0.3 mg of THC in a 12,000 mg bottle and potency within 3 percent of label claim, according to a certificate of analysis from Triverity Laboratories that the page says is available on request.

CareValidate describes itself as the compliance infrastructure behind telehealth brands, with care pathways in menopause, weight loss, longevity and wellness, dermatology, and erectile dysfunction, and with HIPAA, SOC 2 Type II and LegitScript compliance built in. The company claims its platform helps telehealth brands go live in an average of 30 days and achieve a 3:1 return on investment in the first year.

CareValidate co-founder and CEO John Hayde said millions of Americans already use CBD, most of them taking a fraction of a clinically meaningful dose with no clinician involved. “Kazmira built the molecule and the pharmacy. CareValidate built the rails,” he said. CareValidate co-founder and Chief Medical Officer Dr. Jiten Chhabra said the model adds the guardrails providers expect, including eligibility screening, a genuine patient-provider relationship, monitoring protocols and follow-up. “That is the difference between a wellness product and a prescription therapy,” he said. Kazmira co-founders and co-CEOs Priyanka Sharma and Pulak Sharma said they have worked for more than a decade to demonstrate that cannabinoids belong inside a more rigorous, healthcare-centered model and that, with this partnership, they are no longer building that vision alone.

CareValidate’s page notes that compounded medications are not FDA-approved, that not all patients are eligible, and that no prescription or outcome is guaranteed. The announcement states that telehealth programs offering Prescription Cannabis Therapy through the CareValidate platform are expected to begin enrolling patients in October 2026.